YMTX / Yumanity Therapeutics Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-37695 Commission File Number KINETA, INC. (By Kineta, LLC, as successor by merger to Kin

AMENDED AND RESTATED CERTIFICATE OF FORMATION Kineta, LLC

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF FORMATION OF Kineta, LLC 1. The name of the Company is Kineta, LLC. 2. The address of the registered office of the Company is Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808. 3. The Company’s registered agent at such registered office address is Corporation Service Company.

TuHURA Biosciences Completes Acquisition of Kineta Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody(mAb) to TuHURA’s late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA i

Exhibit 99.1 TuHURA Biosciences Completes Acquisition of Kineta Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody(mAb) to TuHURA’s late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth tranche of funds from $12.5 million aggregate PIPE f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

No Member may sell, assign, pledge or otherwise transfer or encumber (collectively, “transfer”) all or any part of its interest in the Company, nor shall any Member have the power to substitute a transferee in its place as a substitute Member, withou

Exhibit 3.2 AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF KINETA, LLC This AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (“Agreement”) is made and entered into effect as of June 30, 2025, by and between Kineta, LLC, a Delaware limited liability company (the “Company”), and TuHURA Biosciences, Inc., a Nevada corporation (“Sole Member”). RECITALS (A) The Company was formed a

As filed with the Securities and Exchange Commission on June 30, 2025

S-8 POS 1 d931841ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. 333-210521 Registration No. 333-218544 Registration No. 333-223664 Registration No. 333-230155 Registration No. 333-237181 Registration No. 333-252691 Registration No. 333-252692 Registration No. 333-256853 Registration No. 333-268969 UNITED STATES SECURITIES AND EXCHANGE COMM

As filed with the Securities and Exchange Commission on June 30, 2025

As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

POS AM As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

POS AM As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

POS AM As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

S-8 POS As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

S-8 POS 1 d931841ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on June 30, 2025 Registration No. 333-210521 Registration No. 333-218544 Registration No. 333-223664 Registration No. 333-230155 Registration No. 333-237181 Registration No. 333-252691 Registration No. 333-252692 Registration No. 333-256853 Registration No. 333-268969 UNITED STATES SECURITIES AND EXCHANGE COMM

As filed with the Securities and Exchange Commission on June 30, 2025

S-8 POS As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

As filed with the Securities and Exchange Commission on June 30, 2025

POS AM As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Exhibit 99.1 TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals TAMPA, Fla., and Seattle, Wash., June 23, 2025 — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) (“K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 TUHURA BIOSCIENCES,

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy Secur

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

KINETA, INC. KINETA, INC. KINETA, INC. KINETA, INC. KINETA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission Fil

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

THE EMPLOYEE understands that this Agreement releases all claims based on facts or omissions occurring on or before the date of this Agreement, even if THE EMPLOYEE does not, at the time THE EMPLOYEE signs this Agreement, have knowledge of those fact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 TUHURA BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 001-37823 99-0360497 (State or Other Jurisdiction of Incorporation) (Commission File

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) Phase 1b/2a trial designed to evalu

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3

TuHURA Biosciences and Kineta Present Updated Results from Kineta’s Phase I-II Study of KVA12123 and TuHURA’s Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual

Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

425 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: TuHURA Biosciences, Inc.

Letter from Marcum LLP, dated March 27, 2025, addressed to the U.S. Securities and Exchange Commission

Exhibit 16.1 March 27, 2025 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Commissioners: We have read the statements made by Kineta, Inc. under Item 4.01 of its Form 8-K dated March 27, 2025. We agree with the statements concerning our Firm in such Form 8-K. We are not in a position to agree or disagree with the other statements of Kineta, Inc. contained th

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

Pre-Funded Warrant dated March 7, 2025.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Securities Exchange Agreement dated March 7, 2025.

Exhibit 10.1 SECURITIES EXCHANGE AGREEMENT This SECURITIES EXCHANGE AGREEMENT (this “Agreement”) is made effective as of March 7, 2025, by and between Kineta, Inc. (the “Issuer”) and Armistice Capital Master Fund Ltd. (the “Holder”), in its capacity as the holder of the Prior Warrants (as defined below). RECITALS WHEREAS, the Holder is the record and beneficial owner of warrants, issued during the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, INC. (E

Subsidiaries of Kineta, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kineta Operating, LLC Delaware Kineta Chronic Pain, LLC Washington Yumanity, Inc. Delaware

Insider Trading Policy

Exhibit 19.1 KINETA, INC. INSIDER TRADING POLICY (Amended and restated on December 16, 2022 and effective as of the Company’s reverse merger; Amended and restated on September 6, 2023) 1. Purpose The following sets forth the policy of Kineta, Inc. (collectively with its subsidiaries, the “Company”) with respect to transactions in the Company’s securities (e.g., common stock), as well as the securi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 KINETA, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

CTF Agreement, dated December 11, 2024, by and between TuHURA and Kineta (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 12, 2024 and incorporated herein by reference).

Exhibit 10.1 CLINICAL TRIAL FUNDING AGREEMENT This Clinical Trial Funding Agreement (this “Agreement”) is made as of December 11, 2024 (the “Effective Date”), by and between TuHURA Biosciences, Inc., a Nevada corporation (“Lender”), and Kineta, Inc., a Delaware corporation (“Borrower”). RECITALS WHEREAS, Borrower is a clinical-stage biopharmaceutical company focused on identifying, acquiring, deve

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpora

Agreement and Plan of Merger, dated December 11, 2024, by and among TuHURA, Kineta, the Merger Subs and the Stockholders Representative (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 12, 2024 and incorporated herein by reference).

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among TUHURA BIOSCIENCES, INC., HURA MERGER SUB I, INC. HURA MERGER SUB II, LLC KINETA, INC. and CRAIG PHILIPS, solely in his capacity as STOCKHOLDERS REPRESENTATIVE Dated as of December 11, 2024 TABLE OF CONTENTS Page Article I THE MERGERS 2 Section 1.1 The Mergers 2 Section 1.2 Closing 3 Section 1.3 Effective Time 3 Section 1.4 Effects of the Mergers 3 Se

Form of TuHURA Support Agreement (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 12, 2024 and incorporated herein by reference).

Exhibit 10.2 FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT TUHURA BIOSCIENCES, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December 11, 2024, is made by and among TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), Kineta, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHEREAS, Pare

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated

Exhibit 99.1 TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA’s therapeutic focus on overcoming primary and acquired resistance

Form of Kineta Support Agreement (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 12, 2024 and incorporated herein by reference).

Exhibit 10.3 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT KINETA, INC. THIS SUPPORT AGREEMENT (this “Agreement”), dated as of December 11, 2024, is made by and among TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), Kineta, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Parent, Hu

Form of Lock-Up Agreement (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 12, 2024 and incorporated herein by reference).

Exhibit 10.4 FORM OF LOCK-UP AGREEMENT December 11, 2024 TuHURA Biosciences, Inc. 10500 University Dr., Suite 110 Tampa, FL, United States 33612 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that TuHURA Biosciences, Inc., a Nevada corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of December 11, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 KINETA, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpora

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update IFx-2.0, a first-in-c

Exhibit 99.1 TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update IFx-2.0, a first-in-c

Exhibit 99.1 TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpora

KANT / Kineta, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-kant093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kineta, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be

Exhibit 99.1 Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in monotherapy (KVA12123 alone) and combination (KVA12123 plus Merck

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 KINETA, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

Settlement Agreement, dated as of September 13, 2024, by and between Kineta, Inc. and ARE-SEATTLE No.17, LLC. (filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-37695) as filed with the SEC on November 6, 2024 and incorporated herein by reference).

Exhibit 10.2 SETTLEMENT AGREEMENT THIS SETTLEMENT AGREEMENT (hereafter “Agreement”) is made and entered into as of the Effective Date (defined below), by and between ARE-SEATTLE NO. 17, LLC, a Delaware limited liability company (“Landlord”) and KINETA, INC., a Washington corporation (“Tenant” or “Kineta”). Landlord and Tenant may be referred herein as a “Party”, or collectively as the “Parties”. R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1

Exhibit 99.1 Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Exhibit 99.1 Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 SEATTLE — (October 4, 2024) Kineta, Inc., (OTC Pink: KANT) (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 TuHURA has extended their exclusivity and right of first offer pursuant to the

Exhibit 99.1 Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 KINETA, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpor

Kineta, Inc Transitioning from Nasdaq to OTC Markets Kineta will be trading under the symbol “KANT”on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of fi

Exhibit 99.1 Kineta, Inc Transitioning from Nasdaq to OTC Markets Kineta will be trading under the symbol “KANT”on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of first offer for Kineta’s KVA12123 program The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patient

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpor

Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpor

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer Effective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for en

Exhibit 99.1 Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer Effective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for enrollment in the clinical study 30 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 an

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States

Exhibit 99.1 Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States SEATTLE — (July 8, 2

Exclusivity and Right of First Offer Agreement, dated as of July 3, 2024, by and between Kineta, Inc. and TuHURA Biosciences, Inc. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on July 8, 2024 and incorporated herein by reference).

Exhibit 10.1 EXCLUSIVITY AND RIGHT OF FIRST OFFER AGREEMENT THIS EXCLUSIVITY AND RIGHT OF FIRST OFFER AGREEMENT (this “Agreement”) is made and dated as of July 3, 2024 (the “Effective Date”), by and between TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), and Kineta, Inc., a Delaware corporation (“Kineta”). TuHURA and Kineta may be referred to herein individually as a “Party” and colle

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, IN

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities Partial response and stable disease reported in combination cohort, and durable stable disease observed

Exhibit 99.1 Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

KA / Kineta, Inc. / Bartoszek Raymond J. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KINETA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) Craig W. Philips President Kineta, Inc. 7683 SE 27th Street, Suite 481 Mercer Island, WA 98040 (206) 378-0400 (Name, Address a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ☐ Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ☒ Definiti

Settlement Agreement and Mutual Release, dated as of April 22, 2024, by and between Kineta, Inc. and RLB Holdings, Connecticut, LLC (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on April 24, 2024 and incorporated herein by reference).

Exhibit 10.1 SEttlement Agreement and MUTUAL Release This Settlement Agreement and Mutual Release (this “Agreement”) is entered into as of April 22, 2024 (the “Effective Date”) by and between Kineta, Inc. (“Kineta”) and RLB Holdings Connecticut, LLC (“RLB”). Kineta and RLB are referred to collectively herein as the “Parties.” Capitalized terms used but not otherwise defined herein shall have the m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2024 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clin

Exhibit 99.1 Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, INC. (E

Subsidiaries of Kineta, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kineta Operating, LLC Delaware Kineta Chronic Pain, LLC Washington Yumanity, Inc. Delaware

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxic

Exhibit 99.1 Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose level in the VISTA-101 trial Cleared fifth of six monotherapy cohorts and second of four combination cohorts i

Compensation Recovery Policy approved on September 6, 2023 and effective as of October 2, 2023.

Exhibit 97.1 KINETA, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on September 6, 2023 and effective as of October 2, 2023) 1. Purpose Kineta, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has adopt

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported Partial response and stable disease reported in combination cohort, and durable stabl

Exhibit 99.1 KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts No dose limiting toxicities observed at any dose level Cleared fifth of six monotherapy cohorts

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) March 2024 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 KINETA, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpora

Separation Agreement by and between Kineta, Inc. and Pauline Kenny, dated March 1, 2024 (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on February 29, 2024 and incorporated herein by reference).

Exhibit 10.2 KINETA, INC. March 1, 2024 Pauline Kenny Dear Pauline: This letter (the “Agreement”) confirms the agreement between you and Kineta, Inc. (the “Company”) regarding the end of your employment with the Company and the resolution of any disputes you have against the Company. 1. Separation Date. Your employment with the Company ended effective March 1, 2024 (the “Separation Date”). You ack

Separation Agreement by and between Kineta, Inc. and Shawn Iadonato, Ph.D., dated March 1, 2024 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on February 29, 2024 and incorporated herein by reference).

Exhibit 10.1 KINETA, INC. March 1, 2024 Shawn Iadonato Dear Shawn: This letter (the “Agreement”) confirms the agreement between you and Kineta, Inc. (the “Company”) regarding the end of your employment with the Company and the resolution of any disputes you have against the Company. 1. Separation Date. Your employment with the Company ended effective March 1, 2024 (the “Separation Date”). You ackn

Kineta Announces Restructuring and Exploration of Strategic Alternatives

Exhibit 99.1 Kineta Announces Restructuring and Exploration of Strategic Alternatives SEATTLE — (February 29, 2024) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed a review of its business, including the status of its programs, resources and

KA / Kineta, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

KA / Kineta, Inc. / Magness Charles - CHARLES MAGNESS (KINETA, INC.) 13G/A Passive Investment

SC 13G/A 1 kineta-charlesmagness13ga.htm CHARLES MAGNESS (KINETA, INC.) 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kineta, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) December 31, 2023 (Date of Event which Requires

KA / Kineta, Inc. / Iadonato Shawn - SHAWN IADONATO (KINETA, INC.) SCHEDULE 13D/A Activist Investment

SC 13D/A 1 kinetashawniadonato-sch13da.htm SHAWN IADONATO (KINETA, INC.) SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KINETA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) Shawn Iadonato, Ph.D. Chief Executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 KINETA, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers Required for Strong Anti-tumor Activit

Exhibit 99.1 Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers Required for Strong Anti-tumor Activity Additional

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) January 2024 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Fourth Amendment to Option and License Agreement (CD27), dated as of December 14, 2023, by and between Gigagen, Inc. and Company (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 15, 2023 and incorporated herein by reference).

EXHIBIT 10.1 FOURTH AMENDMENT TO OPTION AND LICENSE AGREEMENT This Fourth Amendment to Option and License Agreement (the “Amendment”), effective as of December 14, 2023 (the “Fourth Amendment Effective Date”) by and between GigaGen, Inc., a Delaware corporation having a place of business at 75 Shoreway Rd San Carlos, CA, 94070-2726 (“GigaGen”) and Kineta, Inc., a Delaware corporation having a plac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 KINETA, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorpora

KINETA, INC. Up to 890,208 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-275309 PROSPECTUS KINETA, INC. Up to 890,208 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale from time to time, by the selling securityholder (which term as used in this prospectus includes its transferees, pledgees, distributees, donees and successors-in-interest) identified in this p

November 9, 2023

November 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) November 2023 Exhibit 99.

Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker Results Demonstrate Robust VISTA Target Engagement Additional Monotherapy and

Exhibit 99.1 Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker Results Demonstrate Robust VISTA Target Engagement Additional Monoth

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors Initial KVA12123 monotherapy clini

Exhibit 99.1 Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors Initial KVA12123 monotherapy clinical safety, pharmacokinetic, receptor occupancy and bio

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Kineta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to b

As filed with the Securities and Exchange Commission on November 3, 2023

As filed with the Securities and Exchange Commission on November 3, 2023 Registration No.

Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy as a Single Agent and in Combination with Checkpoi

Exhibit 99.1 Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy as a Single Agent and in Combination wit

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporat

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) October 2023 Exhibit 99.

The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) Initial Combination Therapy Clinical Data Anticipated in Q2 2024

Exhibit 99.1 Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) Initial Combination Therapy Clinical Dat

Form of Amendment No. 6 to the Securities Purchase Agreement dated October 13, 2023, by and among the Company and each of the institutional investors named therein (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on October 17, 2023 and incorporated herein by reference).

Exhibit 10.1 KINETA, INC. AMENDMENT NO. 6 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 6 to Securities Purchase Agreement (this “Amendment”) is made as of October 13, 2023, by and among Kineta, Inc., a Delaware corporation (formerly known as Yumanity Therapeutics, Inc.) (the “Company”), and the undersigned Purchasers (as defined in the PIPE Agreement, which is defined below) constituting a

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Exhibit 99.1 Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules SEATTLE, October 4, 2023 –Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement

110,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 780,208 Shares of Common Stock Up to 780,208 Shares of Common Stock Underlying the Pre-Funded Warrants

Filed Pursuant to Rule 424(b)(5) Registration No. 333-269340 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2023) 110,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 780,208 Shares of Common Stock Up to 780,208 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 110,000 shares (the “Shares”) of our common stock, par value $0.001 (the “Common Stock”),

Form of Securities Purchase Agreement, dated as of October 3, 2023 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on October 5, 2023 and incorporated herein by reference).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 3, 2023, between Kineta, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on October 5, 2023 and incorporated herein by reference).

Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT KINETA, INC. Warrant Shares: Initial Exercise Date: October , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof

Form of Common Warrant (filed as Exhibit 4.2 to the Company's Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on October 5, 2023 and incorporated herein by reference).

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Wainwright Warrant (filed as Exhibit 4.3 to the Company's Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on October 5, 2023 and incorporated herein by reference).

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors

Exhibit 99.1 Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors SEATTLE — (October 4, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company f

Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level >90% VISTA Receptor Occupancy Observed in the 30 mg Dosing Cohort VISTA Blocking KVA12123 Engineered to Provide Stron

Exhibit 99.1 Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level >90% VISTA Receptor Occupancy Observed in the 30 mg Dosing Cohort VISTA Blocking KVA12123 Engineered to Provide Strong Single Age

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

to Participate in Upcoming Investor Conferences

Exhibit 99.1 Kineta to Participate in Upcoming Investor Conferences SEATTLE — (August 31, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in September 2023. H.C. Wainwright 25th Annual Global

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Second Amendment to Option and License Agreement (CD27), dated as of December 21, 2022, by and between Gigagen, Inc. and the Company (filed as Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q (File No. 001-37695) as filed with the SEC on August 11, 2023 and incorporated herein by reference).

Exhibit 10.5 SECOND AMENDMENT TO OPTION AND LICENSE AGREEMENT This Second Amendment to Option and License Agreement (the “Amendment”), effective as of December 21, 2022 (the “Second Amendment Effective Date”) by and between GigaGen, Inc., a Delaware corporation having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080 (“GigaGen”) and Kineta, Inc., a Washington corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, INC

Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into early

Exhibit 99.1 Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into early 2025 SEATTLE — (August 11, 2023) Kineta, Inc. (Nasdaq:

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) August 2023 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 KINETA, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporati

Form of Amendment No. 5 to the Securities Purchase Agreement dated July 21, 2023, by and among the Company and each of the institutional investors named therein (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on July 21, 2023 and incorporated herein by reference).

Exhibit 10.1 KINETA, INC. AMENDMENT NO. 5 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 5 to Securities Purchase Agreement (this “Amendment”) is made as of July , 2023, by and among Kineta, Inc., a Delaware corporation (formerly known as Yumanity Therapeutics, Inc.) (the “Company”), and the undersigned Purchasers (as defined in the PIPE Agreement, which is defined below) constituting a major

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS)

EXHIBIT 99.1 Kineta to Receive $5 Million Milestone Payment from Merck Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS) SEATTLE — (June 29, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the ac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

Kineta Expands

EXHIBIT 99.1 Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla SEATTLE — (June 28, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

KINETA, INC. Up to 1,425,179 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-272326 PROSPECTUS KINETA, INC. Up to 1,425,179 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the resale from time to time, by the selling securityholder (which term as used in this prospectus includes its transferees, pledgees, distributees, donees and successors-in-interest) identified in this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) June 2023 Exhibit 99.

June 8, 2023

June 8, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Form of Amendment No. 4 to the Securities Purchase Agreement dated May 1, 2023, by and among the Company and each of the institutional investors named therein (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K/A (File No. 001-37695) as filed with the SEC on June 2, 2023 and incorporated herein by reference).

EXHIBIT 10.1 KINETA, INC. AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 4 to Securities Purchase Agreement (this “Amendment”) is made as of May 1, 2023, by and among Kineta, Inc., a Delaware corporation (formerly known as Yumanity Therapeutics, Inc.) (the “Company”), and the undersigned Purchasers (as defined in the PIPE Agreement, which is defined below). Capitalized terms u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation

As filed with the Securities and Exchange Commission on June 1, 2023

As filed with the Securities and Exchange Commission on June 1, 2023 Registration No.

Filing Fee Table.

EX-FILING FEES 4 ka-exfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Kineta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registra

Third Amendment to Option and License Agreement (CD27), dated as of May 25, 2023, by and between Gigagen, Inc. and the Company (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on May 30, 2023 and incorporated herein by reference)

EXHIBIT 10.2 Certain identified information in this document has been excluded because it is both (i) not material and (ii) the type that the registrant treats as private or confidential, and has been marked with “[***]” to indicate where omissions have been made. THIRD AMENDMENT TO OPTION AND LICENSE AGREEMENT This Third Amendment to Option and License Agreement (the “Amendment”), effective as of

Second Amendment to Option and License Agreement (VISTA), dated as of May 25, 2023, by and between Gigagen, Inc. and the Company (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on May 30, 2023 and incorporated herein by reference).

EXHIBIT 10.1 Certain identified information in this document has been excluded because it is both (i) not material and (ii) the type that the registrant treats as private or confidential, and has been marked with “[***]” to indicate where omissions have been made. SECOND AMENDMENT TO OPTION AND LICENSE AGREEMENT This Second Amendment to Option and License Agreement (the “Amendment”), effective as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

###

EXHIBIT 99.1 Kineta set to join Russell Microcap® Index SEATTLE — (May 24, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

Kineta to Present at Jefferies Healthcare Conference

Exhibit 99.1 Kineta to Present at Jefferies Healthcare Conference SEATTLE — (May 23, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that Shawn Iadonato, Ph.D., Chief Executive Officer at Kineta, will present at the Jefferies Healthcare Conference, being he

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rule

Exhibit 99.1 Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules SEATTLE — (May 11, 2023) Kineta, Inc. (Nasdaq: KA), a

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 KINETA, INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporation)

Form of Amendment No. 4 to the Securities Purchase Agreement dated May 1, 2023, by and among the Company and each of the institutional investors named therein (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on May 2, 2023 and incorporated herein by reference).

EXHIBIT 10.1 KINETA, INC. AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 4 to Securities Purchase Agreement (this “Amendment”) is made as of May 1, 2023, by and among Kineta, Inc., a Delaware corporation (formerly known as Yumanity Therapeutics, Inc.) (the “Company”), and the undersigned Purchasers (as defined in the PIPE Agreement, which is defined below). Capitalized terms u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ☒ Definiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ☐ Definit

Form of Wainwright Warrant (filed as Exhibit 4.3 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on April 21, 2023 and incorporated herein by reference).

EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE

Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on April 21, 2023 and incorporated herein by reference).

EX-4.1 EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT KINETA, INC. Warrant Shares: Initial Exercise Date: April , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h

Form of Securities Purchase Agreement, dated as of April 20, 2023 (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on April 21, 2023 and incorporated herein by reference).

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 20, 2023, between Kineta, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se

948,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 477,179 Shares of Common Stock Up to 477,179 Shares of Common Stock Underlying the Pre-Funded Warrants

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269340 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2023) 948,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 477,179 Shares of Common Stock Up to 477,179 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 948,000 shares (the “Shares”) of our common stock, par value $0.00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2023 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced

EX-99.1 Exhibit 99.1 Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules SEATTLE, April 20, 2023 – Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive a

Form of Common Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on April 21, 2023 and incorporated herein by reference).

EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE

The date of this prospectus supplement is April 20, 2023.

424B5 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-269340 PROSPECTUS SUPPLEMENT (to Prospectus dated January 30, 2023) This prospectus supplement supplements and amends certain information contained in the prospectus supplement dated February 10, 2023 to the prospectus dated January 30, 2023 (collectively, the “February 2023 Prospectus”), relating to the offer and sale of our co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023

Exhibit 99.1 Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023 SEATTLE, April 17, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new VISTA biomarker data and an update on t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated b

EX-99.1 Exhibit 99.1 Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 SEATTLE (April 12, 2023) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the develop

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number)

###

EX-99.1 Exhibit 99.1 Kineta to Present at 22nd Annual Needham Healthcare Conference SEATTLE — (April 3, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that Shawn Iadonato, Ph.D., CEO will present at the 22nd Annual Needham Healthcare Conference, being held

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number

Subsidiaries of Kineta, Inc.

Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kineta Operating, LLC Delaware Kineta Chronic Pain, LLC Washington Kineta Viral Hemorrhagic Fever, LLC Washington Yumanity, Inc. Delaware

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction (Commission (IRS Employer of incorporatio

Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by End of 2023 Successfully Completed the Reverse Merger with Nasdaq-listed Yumanity Therapeutics

Exhibit 99.1 Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by End of 2023 Successfully Completed the Reverse Merger with Nasdaq-listed Yumanity Therapeutics SEATTLE — (March 31, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology compa

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37695 KINETA, INC. (E

Form of Amendment No. 3 to the Securities Purchase Agreement dated March 29, 2023, by and among the Company and each of the institutional investors named therein (filed as Exhibit 10.18 to the Company’s Annual Report on Form 10-K (File No. 001-37695) as filed with the SEC on March 31, 2023 and incorporated herein by reference).

Exhibit 10.18 KINETA, INC. AMENDMENT NO. 3 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 3 to Securities Purchase Agreement (this “Amendment”) is made as of March , 2023, by and among Kineta, Inc., a Delaware corporation (formerly known as Yumanity Therapeutics, Inc.) (the “Company”), and the undersigned Purchasers (as defined in the PIPE Agreement, which is defined below). Capitalized terms

Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as,

Exhibit 99.1 April 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as, but not limited to, “believe,” “

Description of Registrant’s Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (filed as Exhibit 4.2 to the Company’s Annual Report on Form 10-K (File No. 001-37695) as filed with the SEC on March 31, 2023 and incorporated herein by reference).

Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Kineta, Inc. (the “Company,” “us,” “we,” or “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. This description also summarizes relevant provisions

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 KINETA, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number

###

Exhibit 99.1 Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023 SEATTLE, March 22, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will present its VISTA clinical program at the American Association for Cancer Research (AAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number)

###

Exhibit 99.1 Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference SEATTLE, March 8, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, will present a corporate overview at the Op

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number)

Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target

Exhibit 99.1 Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target SEATTLE, March 6, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today it will host a virtual Key Opinion Leader (KOL) event on VISTA as an immuno-oncology target on Monday

####

EX-99.1 Exhibit 99.1 Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board Seattle, WA — (March 1, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the appointment of Myriam Chalabi, M.D. and Evan Ya-Wen Yu, M.D. to t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2023 KINETA, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 KINETA, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Num

KA / Kineta Inc / CBI USA, Inc. - SC 13G Passive Investment

SC 13G 1 d465720dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kineta, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) December 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria

KA / Kineta Inc / Magness Charles - SC 13G Passive Investment

SC 13G 1 d462941dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kineta, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropria

Joint Filing Agreement

EX-99.1 2 d465720dex991.htm EX-99.1 Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2023 with respect to the Common Stock, $0.001 par value per share of Kineta, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuan

Joint Filing Agreement, dated as of February 14, 2023, by and between the Reporting Persons.

EX-99.1 2 d463568dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of common stock of Kineta, Inc. The undersigned acknowled

KA / Kineta Inc / Iadonato Shawn - SC 13D Activist Investment

SC 13D 1 d457532dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 KINETA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) Shawn Iadonato, Ph.D. Chief Executive Officer Kineta, Inc. 219 Terry Ave. N., Suite 300 Seattle, WA 98109 (206)

KA / Kineta Inc / Bartoszek Raymond J. - SC 13D Activist Investment

SC 13D 1 d463568dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D Under the Securities Exchange Act of 1934 KINETA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 49461C 102 (CUSIP Number) Shawn Iadonato, Ph.D. Chief Executive Officer Kineta, Inc. 219 Terry Ave. N., Suite 300 Seattle, WA 98109 (206)

As filed with the Securities and Exchange Commission on February 10, 2023.

As filed with the Securities and Exchange Commission on February 10, 2023. Registration No. 333-261489 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-261489 UNDER THE SECURITIES ACT OF 1933 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 20-8436652 (State or other jurisdiction of

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Num

Open Market Sale AgreementSM, dated February 10, 2023, by and between the Company and Jefferies LLC (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on February 10, 2023 and incorporated herein by reference).

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM February 10, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Kineta, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, pa

Up to $17,500,000 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269340 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2023) Up to $17,500,000 Common Stock We have entered into an Open Market Sale AgreementSM (the “sale agreement”) with Jefferies LLC (“Jefferies”), relating to the offer and sale of shares of our common stock, par value $0.001. In accordance with the terms of t

KINETA, INC. 649,346 Shares of Common Stock Common Stock Preferred Stock Depositary Shares Debt Securities Purchase Contracts

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-269340 PROSPECTUS KINETA, INC. 649,346 Shares of Common Stock $200,000,000 Common Stock Preferred Stock Depositary Shares Debt Securities Warrants Purchase Contracts Rights Units From time to time, we may offer and sell up to $200,000,000 in aggregate principal amount, in one or more series or issuances and on terms that we wi

January 26, 2023

January 26, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Form of Senior Indenture between the Registrant and one or more trustees to be named.

Exhibit 4.3 KINETA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.0

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kineta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carr

Form of Subordinated Indenture between the Registrant and one or more trustees to be named.

Exhibit 4.4 KINETA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.0 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sectio

As filed with the Securities and Exchange Commission on January 20, 2023

Table of Contents As filed with the Securities and Exchange Commission on January 20, 2023 Registration No.

January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq)

Exhibit 99.1 January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) Disclaimers and other information Cautionary Statements Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: Kin

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2023 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2022 KINETA, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2022 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Num

Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Kineta, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

As filed with the Securities and Exchange Commission on December 22, 2022

As filed with the Securities and Exchange Commission on December 22, 2022 Registration No.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On June 5, 2022, Yumanity Therapeutics, Inc. (Yumanity) and Kineta, Inc. (Kineta) entered into an agreement and plan of merger, as amended on December 5, 2022 (Merger Agreement). On December 16, 2022, the merger became effective and Kineta became a wholly owned subsidiary of Yumanity and the surviving corporation (the Merger

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 KINETA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commission File Num

Separation Agreement by and between the Company and Michael Wyzga, dated December 16, 2022 (filed as Exhibit 10.16 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 10.16 CONFIDENTIAL December 16, 2022 Michael Wyzga Re: Separation Upon Closing of Merger with Kineta, Inc. Dear Michael: The purpose of this letter agreement (the ?Agreement?) is to confirm the terms of your separation of employment from Yumanity Therapeutics, Inc. and its subsidiaries (the ?Company?) upon the Closing, as such term is defined in the Agreement and Plan of Merger, dated as o

Certificate of Amendment of Fifth Amended and Restated Certificate of Incorporation of the Company, dated December 16, 2022 (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF YUMANITY THERAPEUTICS, INC. (a Delaware corporation) Yumanity Therapeutics, Inc. (the ?Company?), a company organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. Upon the effectiveness of this Certificat

KINETA MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.4 KINETA MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes in Exhibit 99.2 included in this Current Report on Form 8-K. This discussion contains forward-looking state

Kineta, Inc. 2022 Equity Incentive Plan and associated forms (filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 10.6 KINETA, INC. 2022 EQUITY INCENTIVE PLAN Effective December 16, 2022 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel to ensure the Company?s success and accomplish the Company?s goals; (b) to incentivize Employees, Directors and Independent Contractors with long-term equity-based compensation to align their interests with th

Separation Agreement by and between the Company and Devin Smith, dated December 16, 2022 (filed as Exhibit 10.17 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 10.17 CONFIDENTIAL December 16, 2022 Devin Smith Re: Separation Upon Closing of Merger with Kineta, Inc. Dear Devin: The purpose of this letter agreement (the ?Agreement?) is to confirm the terms of your separation of employment from Yumanity Therapeutics, Inc. and its subsidiaries (the ?Company?) upon the Closing, as such term is defined in the Agreement and Plan of Merger, dated as of Ju

Letter to the Securities and Exchange Commission from PricewaterhouseCoopers LLP, dated December 22, 2022.

Exhibit 16.1 December 22, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Kineta, Inc. (formerly known as Yumanity Therapeutics, Inc.) (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Kineta, Inc. dated December 16, 2022. We agree wi

Certificate of Amendment of Fifth Amended and Restated Certificate of Incorporation of the Company, dated December 16, 2022 (filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF YUMANITY THERAPEUTICS, INC. (a Delaware corporation) Yumanity Therapeutics, Inc. (the ?Company?), a company organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the corporation is Yumanity T

RISK FACTORS

Exhibit 99.5 RISK FACTORS Investing in the securities of Kineta, Inc. (?Kineta?) involves significant risks and uncertainties. Before making an investment decision, you should carefully consider the risks and uncertainties described below, together with any subsequent updates described in Kineta?s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Kineta c

KINETA, INC. Condensed Consolidated Balance Sheets (in thousands, except per share amounts) September 30, December 31, 2022 2021 (unaudited) Assets Current assets: Cash $ 2,810 $ 11,144 Prepaid expenses and other current assets 2,103 73 Total current

Exhibit 99.2 KINETA, INC. Condensed Consolidated Balance Sheets (in thousands, except per share amounts) September 30, December 31, 2022 2021 (unaudited) Assets Current assets: Cash $ 2,810 $ 11,144 Prepaid expenses and other current assets 2,103 73 Total current assets 4,913 11,217 Property and equipment, net 206 189 Operating right-of-use asset 1,383 1,872 Restricted cash 75 75 Total assets $ 6,

Separation Agreement by and between the Company and Richard Peters, dated December 16, 2022 (filed as Exhibit 10.15 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 10.15 CONFIDENTIAL December 16, 2022 Richard Peters, M.D., Ph.D. [***] Re: Separation Upon Closing of Merger with Kineta, Inc. Dear Richard: The purpose of this letter agreement (the ?Agreement?) is to confirm the terms of your separation from employment with Yumanity Therapeutics, Inc. and its subsidiaries (the ?Company?) upon the Closing, as such term is defined in the Agreement and Plan

KINETA’S BUSINESS

Exhibit 99.6 KINETA?S BUSINESS Overview Kineta, Inc. (?Kineta?) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients? lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy.

Kineta Completes Reverse Merger with Yumanity Therapeutics

Exhibit 99.1 Kineta Completes Reverse Merger with Yumanity Therapeutics Shares of Kineta to commence trading on Nasdaq under new ticker symbol ?KA? on December 19, 2022 Seattle, WA ? (December 19, 2022) Kineta, Inc. (?Kineta? or the ?Company?), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the compl

Fourth Amended and Restated By-laws of the Company, dated December 16, 2022 (filed as Exhibit 3.3 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 22, 2022 and incorporated herein by reference).

Exhibit 3.3 FOURTH AMENDED AND RESTATED BY-LAWS OF KINETA, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at such hour and date as the Board of Directors of the Corporation (the ?Board of Directors?) shall each year fix. The Annual Meeting may be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 YUMANITY THER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 YUMANITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 YUMANITY THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 YUMANITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Comm

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 YUMANITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Comm

Disclaimers and other information This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by w

EX-99.1 Exhibit 99.1 December 6, 2022 JMP Securities Hematology & Oncology Summit Developing next-generation immunotherapies that address cancer immune resistance Disclaimers and other information This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be id

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 YUMANITY THERAPE

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 YUMANITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 YUMANITY THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 YUMANITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commi

Form of Amendment No. 2 to the Registration Rights Agreement, by and between the Company and each of the institutional investors named therein dated December 5, 2022 (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 001-37695) as filed with the SEC on December 5, 2022 and incorporated herein by reference).

Exhibit 10.4 YUMANITY THERAPEUTICS, INC. AMENDMENT NO. 2 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 2 to Registration Rights Agreement (this ?Amendment?) is made as of December , 2022, by and among Yumanity Therapeutics, Inc., a Delaware corporation (the ?Company?), and the undersigned Purchasers (as defined in the Agreement, which is defined below). Capitalized terms used herein but not

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 YUMANITY THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 YUMANITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37695 20-8436652 (State or other jurisdiction of incorporation) (Commi

YOUR VOTE IS VERY IMPORTANT

Filed Pursuant to Rule 424(b)(3) Registration No. 333-267127 Prospectus Supplement (To Prospectus dated November 10, 2022) ? ? ? ? YOUR VOTE IS VERY IMPORTANT To the Stockholders of Yumanity Therapeutics, Inc. and Shareholders of Kineta, Inc.: Since the filing of our proxy statement/prospectus/information statement with the United States Securities and Exchange Commission (the ?SEC?), Yumanity The